Cellares, the Integrated Development and Manufacturing Organization (IDMO) applying an Industry 4.0 approach to cell therapy, has raised $20.0M in Series d funding. The investment, led by ARK Investment Management LLC, will support the company's efforts to mass manufacture living drugs.
Headquartered in South San Francisco, Cellares enables drug sponsors to develop, scale, and commercialize cell therapies through its global network of IDMO Smart Factories. Its fully automated Cell Shuttle platform, which has received the FDA's Advanced Manufacturing Technology designation, is central to delivering industry-leading manufacturing economics and higher process success rates.
